Select country set
language
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-132-3p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0052H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Tissue extract, Cell culture lysate, Whole blood

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

6.25 – 0.2 amol/μl

Limit of Detection

0.07 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 7.7%

Inter-assay (Run-to-Run)

n = 5,
CV = 11.0%

Spiking Recovery

92.4%

Dilution Linearity

103.8%

Specificity

Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-132-3p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology, Neurodegenerative disease

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-132-3p is downregulated in many types of carcinomas. miR-132-3p suppressed the migration and invasion of breast carcinoma cells. Down regulation of miR-132-3p has also been found in colorectal cancer (CRC). Overexpression of long non-coding RNA and CAMP Responsive Element Binding Protein 5 resulted in the enhancement of proliferation, metastasis, migration and the inhibition of apoptosis in CRC cells, while miR-132-3p led to the opposite result. miR-132-3p was found to be down-regulated during the osteogenic differentiation of ligamentum flavum cells and negatively regulated osteoblast differentiation. In addition, miR-132-3p was dramatically down-regulated in CD19+ lymphocytes isolated from peripheral blood mononuclear cells (PBMCs) of mantle cell lymphoma patients.

hsa-miR-132-3p is considered one of the angiogenic miRNAs. The circulating miR-132-3p showed different expression levels between mesothelioma patients and asbestos-exposed controls. Overexpressing miR-132-3p or knocking down taurine upregulated gene 1 significantly alleviated ischemia-reperfusion induced AMI (acute myocardial infarction) in vivo.

Increase of miR-132-3p expression in white blood cells of neuropathy patients has been compared to healthy controls. miR-132-3p expression was also slightly up-regulated in sural nerve biopsies from neuropathy patients suffering from neuropathic pain compared to those without pain. Levels of miR-132-3p in neurally-derived plasma extracellular vesicles showed good sensitivity and specificity to diagnose Alzheimer's disease (AD), but did not effectively separate individuals with AD and mild cognitive impairment (MCI) from controls. It was observed that miR-132-3p and miR-146a-5p expressions were significantly decreased in the serum samples of patients with Parkinson’s disease (PD) compared to those in the healthy volunteers. Moreover, the expressions of miR-132-3p and miR-146a-5p showed a dramatic decrease in severe PD patients as compared to patients with less severe PD. Both miRNAs appear be useful as promising biomarkers for early diagnosis of PD.

Summary References (9)

References to miR-132-3p

  • Cha DJ, Mengel D, Mustapic M, Liu W, Selkoe DJ, Kapogiannis D, Galasko D, Rissman RA, Bennett DA, Walsh DM. miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer's Patients. Front Neurosci. 2019 Nov 26;13:1208. doi: 10.3389/fnins.2019.01208. PMID: 31849573; PMCID: PMC6902042. See more on PubMed
  • Leinders M, Üçeyler N, Pritchard RA, Sommer C, Sorkin LS. Increased miR-132-3p expression is associated with chronic neuropathic pain. Exp Neurol. 2016 Sep;283(Pt A):276-86. doi: 10.1016/j.expneurol.2016.06.025. Epub 2016 Jun 24. PMID: 27349406; PMCID: PMC4992589. See more on PubMed
  • Li G, Liu K, Du X. Long Non-Coding RNA TUG1 Promotes Proliferation and Inhibits Apoptosis of Osteosarcoma Cells by Sponging miR-132-3p and Upregulating SOX4 Expression. Yonsei Med J. 2018 Mar;59(2):226-235. doi: 10.3349/ymj.2018.59.2.226. PMID: 29436190; PMCID: PMC5823824. See more on PubMed
  • Qu X, Chen Z, Fan D, Sun C, Zeng Y. MiR-132-3p Regulates the Osteogenic Differentiation of Thoracic Ligamentum Flavum Cells by Inhibiting Multiple Osteogenesis-Related Genes. Int J Mol Sci. 2016 Aug 20;17(8):1370. doi: 10.3390/ijms17081370. PMID: 27556448; PMCID: PMC5000765. See more on PubMed
  • Shu Y, Qian J, Wang C. Aberrant expression of microRNA-132-3p and microRNA-146a-5p in Parkinson's disease patients. Open Life Sci. 2020 Sep 2;15(1):647-653. doi: 10.1515/biol-2020-0060. PMID: 33817253; PMCID: PMC7747498. See more on PubMed
  • Su Q, Liu Y, Lv XW, Dai RX, Yang XH, Kong BH. LncRNA TUG1 mediates ischemic myocardial injury by targeting miR-132-3p/HDAC3 axis. Am J Physiol Heart Circ Physiol. 2020 Feb 1;318(2):H332-H344. doi: 10.1152/ajpheart.00444.2019. Epub 2019 Dec 20. Erratum in: Am J Physiol Heart Circ Physiol. 2020 Mar 1;318(3):H729. PMID: 31858814. See more on PubMed
  • Weber DG, Gawrych K, Casjens S, Brik A, Lehnert M, Taeger D, Pesch B, Kollmeier J, Bauer TT, Johnen G, Brüning T. Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma. Dis Markers. 2017;2017:9280170. doi: 10.1155/2017/9280170. Epub 2017 Feb 21. PMID: 28321148; PMCID: PMC5339541. See more on PubMed
  • Wu B, Li J, Wang H, Wu Q, Liu H. MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11. Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2197-2208. doi: 10.1007/s00210-020-01834-0. Epub 2020 Feb 10. PMID: 32040593. See more on PubMed
  • Zhang M, Li Y, Wang H, Yu W, Lin S, Guo J. LncRNA SNHG5 affects cell proliferation, metastasis and migration of colorectal cancer through regulating miR-132-3p/CREB5. Cancer Biol Ther. 2019;20(4):524-536. doi: 10.1080/15384047.2018.1537579. Epub 2018 Nov 5. PMID: 30395767; PMCID: PMC6422517. See more on PubMed
Related Products Docs